All News
AS, Lupus and Subclinical RA: What I'm looking forward to at ACR22
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.
Read Article
ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
d
EurekAlert!
New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).
Read Article
Update: axSpA Recommendations
d
EurekaAlert!
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016.
Read Article
Chronic Pain increased from 2010-2919. A cross-sectional study of 46 420 respondents, shows nonpharmacologic Rx increased [aOR 2.72] & was greater than opioids for chronic, but not surgical pain. Govt policy & practice guidelines have helped. https://t.co/31oS0xWRMW https://t.co/IvkDRJQvT8
Links:
Dr. John Cush RheumNow ( View Tweet)
Sleep Habits study from NHANES - 9004 adults >20 yrs (2017-2020) finds mean sleep duration 7.6 hrs on workdays & 8.2 hrs on free days; 23% slept <7 hrs & 25% went to bed > midnight. Nearly 30% had trouble sleeping (daytime sleepiness 27%) https://t.co/Uc7nL4q3fm https://t.co/qvCwqbsez1
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow RheumNow reporter, Dr. Eric Dein, for real-time #ACR22 coverage! https://t.co/NZkVd2A989
Dr. John Cush RheumNow ( View Tweet)
Our newest RheumNow reporter, Dr. Michael Putman , will be covering SLE and Vasculitis at #ACR22 this year.
“Looking forward to seeing all my friends and colleagues in person!”-Dr. Putnam
Follow him @EBRheum for real-time coverage! https://t.co/DpFa0zwzPX
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - 1st Line Anakinra
New-onset systemic JIA - how will you treat? #ACR22
https://t.co/cxG6ZcBXUv https://t.co/YCXD4z9BQ7
Links:
Dr. John Cush RheumNow ( View Tweet)
Video Telehealth Willingness Increased During Pandemic
Americans’ willingness to use video telehealth has increased since the beginning of the pandemic, rising most sharply among Black Americans and people with less education, according to a new study.
https://t.co/oi3C2A7yJt https://t.co/H8AhiXeU3r
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment
https://t.co/FI5k6LIKrO https://t.co/I0F1wJNBDc
Links:
Dr. John Cush RheumNow ( View Tweet)
Plaquenil (HCQ) reduces #SLE mortality. Metanalysis (21 studies, 26,037 pts). Pooled findings - HCQ significantly reduced SLE mortality (HR 0.46); HCQ also reduced mortality in SLE pts w/ renal (HR=0.43), & cardiopulmonary dz (HR=0.37) https://t.co/fsHaN8wR17 https://t.co/MW8cvavzBC
Links:
Dr. John Cush RheumNow ( View Tweet)
Opportunistic Infections with JAK inhibitors in RA
Winthrop and colleagues have reviewed the occurrence of OIs associated with the use of JAK inhibitors in patients with RA, showing that Herpez zoster (HZ) was the most common OI reported.
https://t.co/CtFcnHiWKS https://t.co/qKU51vLxaP
Links:
Dr. John Cush RheumNow ( View Tweet)
We're excited to have Dr. Aurelia Najm back as an #ACR22 RheumNow reporter!
"I look forward to learning about developments in the field and finally meet with colleagues and collaborators from all over the world. "
-Dr. Najm
Follow @AurelieRheumo for real time #ACR22 coverage! https://t.co/o6Mhobt2BR
Dr. John Cush RheumNow ( View Tweet)
Dr. Robert Chao is back as a RheumNow reporter for a third year.
"I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year! "
Follow @doctorRBC for real-time #ACR22 coverage! https://t.co/j6FNra7aZq
Dr. John Cush RheumNow ( View Tweet)
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR22 meeting in Philadelphia.
https://t.co/STvWZMS7xS https://t.co/oQt3ZMyjEN
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Seropositive Arthralgia (abstract #1604)
42 yr old woman with +RF and Arthralgias only. How to treat?
https://t.co/MgPFHa0CAd https://t.co/Aqlrc6rOSt
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with AIIRD.
https://t.co/VrdNggfMfG https://t.co/WARs0YJLZs
Links:
Dr. John Cush RheumNow ( View Tweet)
12 pts w/ new onset IgA vasculitis (IgAV) post COVID- 19 vaccination (5F; age 52 yrs) - 10 had mRNA & 2 viral vector Vax. Time from Vax to Sxs=11.5 d; 8/12 had vasculitis w/ 1st dose; all skin (7 Jts, 4GI, 2 renal). All Rx w/ steroids https://t.co/eCcUkGeAwV https://t.co/VU1LwFxITC
Links:
Dr. John Cush RheumNow ( View Tweet)
Cluster analysis of 112 SLE pts looked at Erosive arthritis. Arthritis seen in 73%, arthralgia in 27%, erosive arthritis in 26%. Cluster that included erosive Dz also seen w/ CNS EL, serositis, Pos tests for ACPA, Carp, Sm, RNP, Dkk1 https://t.co/c7SLmFtweu https://t.co/qt9FdA1SBa
Links:
Dr. John Cush RheumNow ( View Tweet)
NY Times reports preprint article showing that taking Paxlovid w/in 5 days of COVID Test+ lowers risk of Long COVID Sxs by 26%. EMR study of 56,340 COVID pts w/ >= risk factor for severe infx; 9,217 Rx w/ Paxlovid had lesss post-Covid Sxs > 90D https://t.co/JyWEoJbUc7 https://t.co/xvTVNugwhJ
Links:
Dr. John Cush RheumNow ( View Tweet)